Below is a selection of coverage from studies that generated significant media attention at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI). You may also wish to visit the Press Conference Webcasts page for discussions on key sessions at CROI 2019.
Note: The indication LB beside some abstract numbers below indicated a late-breaking abstract which represent studies of data analyzed after the general abstract submission deadline which also meet a high threshold of scientific merit.
29 LB SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT
Presenting Author: Ravindra Gupta, University College London, London, UK
- The New York Times: H.I.V. Is Reported Cured in a Second Patient, a Milestone in the Global AIDS Epidemic, (March 4, 2019)
- The Washington Post: A Decade After the First Person Was Cured of HIV, a Second Patient is in Long-term Remission (March 4, 2019)
- Reuters, London HIV Patient Becomes World's Second AIDS Cure Hope (March 4, 2019)
- Associated Press, 2nd Man Apparently Free of AIDS Virus Following Stem Cell Transplant, (March 4, 2019)
- Science, Has a Second Person with HIV Been Cured? (March 4, 2019)
39 LB RANDOMIZED TRIAL OF RALTEGRAVIR-ART VS EFAVIRENZ-ART WHEN INITIATED DURING PREGNANCY
Presenting Author: Mark Mirochnick, Boston University, Boston, MA, US
- Contagion Live, Viral Load Decline Achieved Faster in Pregnant Women Treated with Raltegravir (March 5, 2019)
- AIDSMap, Integrase Inhibitors Give Greater Chance of Viral Suppression at Delivery in Pregnant Women (March 6, 2019)
- Infectious Disease News, Studies Support Use of Integrase inhibitors in Pregnant Women with HIV (March 6, 2019)
40 LB RCT OF DOLUTEGRAVIR VS EFAVIRENZ-BASED THERAPY INITIATED IN LATE PREGNANCY: DOLPHIN-2
Presenting Author: Saye Khoo, University of Liverpool, Liverpool, UK
- HIV i-base, Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2 (March 6, 2019)
- MedPage Today, Integrase Inhibitors Drop Virus Faster in Pregnant HIV Patients (March 7, 2019)
- The Body, Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows (March 7, 2019)
47 INCIDENT SYPHILIS RATES AND PREDICTORS IN US WOMEN WITH HIV, 2005-2016
Presenting Author: Jodie Dionne-Odom, University of Alabama at Birmingham, Birmingham, AL, US
- Infectious Disease News, IV Drug Use, HCV Predict Syphilis in Women with HIV (March 5, 2019)
- MedPage Today, Upswing of Syphilis in Women With HIV (March 6, 2019)
- Medscape, Women Have High Syphilis Rates, Too (March 6, 2019)
53 LB POINT-OF-CARE VIRAL LOAD TESTING IMPROVES HIV VIRAL SUPPRESSION AND RETENTION IN CARE
Presenting Author: Paul Drain, University of Washington, Seattle, WA, US
- Science Speaks, CROI 2019: Point-of-Care Viral Load Testing Improves HIV Outcomes, Researchers Say (March 5, 2019)
- AIDSMap, Point-of-Care Viral Load Testing Improves Treatment Outcomes and Retention in Care (March 5, 2019)
- MedPage Today, Point-of-Care HIV Load Testing Keeps Patients at Clinic (March 6, 2019)
80 LB SAFETY & PK OF WEEKLY RIFAPENTINE/ISONIAZID (3HP) IN ADULTS WITH HIV ON DOLUTEGRAVIR
Presenting Author: Kelly Dooley, Johns Hopkins University School of Medicine, Baltimore, MD, US
- Infectious Disease News, ‘Reassured’: Short TB Treatment Safe in Adults with HIV on Dolutegravir (March 8, 2019)
- AIDSMap, Co-administration of Dolutegravir-based Treatment and Short Course of Rifapentine/Isoniazid (3HP) Well Tolerated in People Living with HIV (March 12, 2019)
- HIV i-base, Dolutegravir Can Be Given with 3HP to Prevent TB without Dose Adjustment (March 12, 2019)
92 LB IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA: HPTN071 (POPART)
Presenting Author: Richard Hayes, London School of Hygiene & Tropical Medicine, London, UK
- Sunday Times, New HIV Infections Can Be Prevented, Million-people Trial Shows (March 5, 2019)
- AllAfrica, Southern Africa: Major New Study Points Way to Cut HIV Infections (March 5, 2019)
- The Telegraph, Testing Everyone for HIV Leads to Drop in Infection By a Third (March 6, 2019)
- The Independent, Tutu’s HIV Trials Can Cut the Rate by 30% (March 7, 2019)
- Science, Largest Ever HIV Prevention Study Delivers Sobering Message (March 11, 2019)
104 LB THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS
Presenting Author: Charles Hare, University of California San Francisco, San Francisco, CA, US
- Beta, New Research: Is Descovy a New Option for PrEP? (March 7, 2019)
- Medscape, 'Grappling' With the Value of Descovy for HIV PrEP (March 7, 2019)
- POZ, Descovy PrEP Works Equally Well, May Be Safer for Kidneys and Bones (March 8, 2019)
139 LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS
Presenting Author: Susan Swindells, University of Nebraska Medical Center, Omaha, NE, US
- Associated Press, Monthly Shots Control HIV as Well as Pills in 2 Big Studies (March 7, 2019)
- Contagion Live, ATLAS: Long-Acting Cabotegravir + Rilpivirine Non-Inferior to Oral ART at 48 Weeks (March 7, 2019)
- MedPage Today, Monthly HIV Treatment on Par With Daily Regimen (March 8, 2019)